Accueil Healthcare Nuclear Medicine and Radiopharmaceuticals Manufacturing Market Research Report 2020-2030

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market Research Report 2020-2030

0
0
117

The production of radiopharmaceuticals as compared to traditional pharmaceuticals is a multifaceted procedure and requires specialized facilities, equipment and operational expertise. Further, owing to its inherent hazardous nature, radiopharmaceuticals have a complex regulatory market authorization process. Consequently, a number of innovator companies have demonstrated a preference for outsourcing radiopharmaceutical manufacturing to contract service providers.

Roots Analysis is pleased to announce the publication of its recent study, titled, “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

The USD 6+ billion (by 2030) financial opportunity associated with nuclear medicine and radiopharmaceuticals manufacturing, has been analyzed across the following segments:

Target Disease Indication

  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Lupus Nephritis
  • Melanoma
  • Multiple Myeloma
  • Primary Sjögren’s Syndrome
  • Others

Target Immune Checkpoint

  • B7-H3
  • CD38
  • CD40
  • CD47
  • Others

Mechanism of Action

  • Inhibitory
  • Stimulatory

Therapeutic Modality

  • Monoclonal Antibody
  • Small Molecule

Type of Therapy

  • Monotherapy
  • Combination Therapy

Route of Administration

  • Intravenous
  • Subcutaneous
  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

The Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Advanced Accelerator Applications
  • Belgian Nuclear Research Center (SCK•CEN)
  • Cardinal Health
  • China Isotope & Radiation Corporation
  • Curium Pharma
  • DuChemBio
  • Eckert & Ziegler
  • Eczacibasi-Monrol
  • GE Healthcare
  • Jubilant DraxImage
  • Lantheus Medical Imaging
  • Nihon Medi-Physics
  • Nordion
  • PETNET Solutions
  • SinoTau Pharmaceuticals
  • SOFIE

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Current Market Landscape

5. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Current Market Landscape

6. Nuclear Medicine and Radiopharmaceuticals Manufacturers in North America

7. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Europe

8. Nuclear Medicine and Radiopharmaceuticals Manufacturers in Asia-Pacific And Rest of The World

 

9. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Company Competitiveness Analysis

10. Partnerships and Collaborations

11. Production and Supply Chain of Medical Isotope Molybdenum-99 (Technetium-99m)

12. Market Forecast and Opportunity Analysis

13. Concluding Remarks

14. Executive Insights

15. Appendix 1: Tabulated Data

16. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Charger d'autres articles liés
Charger d'autres écrits par rootsanalysis
Charger d'autres écrits dans Healthcare

Laisser un commentaire

Consulter aussi

Psychedelic Therapeutics Market is estimated to be worth over USD 6.5 billion by 2030

Psychedelic substances have been demonstrated to interact with a variety of neurotransmitt…